Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Up 6.1% in November

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 22,600 shares, a growth of 6.1% from the October 31st total of 21,300 shares. Based on an average daily trading volume, of 30,300 shares, the short-interest ratio is presently 0.7 days. Currently, 0.2% of the company’s stock are sold short.

Akari Therapeutics Stock Performance

AKTX stock traded down $0.01 during midday trading on Wednesday, reaching $1.28. 8,951 shares of the company’s stock traded hands, compared to its average volume of 22,492. The firm’s fifty day moving average price is $2.27 and its 200-day moving average price is $2.85. Akari Therapeutics has a 52 week low of $0.90 and a 52 week high of $4.40.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Akari Therapeutics in a research note on Wednesday. They issued a “sell” rating for the company.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.